중국의 생물제제 수탁제조 시장 : 업계 동향과 세계 예측 - 제품 유형별, 사용 발현 시스템별, 사업 규모별, 기업 규모별, 생물제제 유형별

China Biologics Contract Manufacturing Market: Industry Trends and Global Forecasts - Distribution by Type of Product, Expression System Used, Scale of Operation, Company Size and Type of Biologic

US $ 4,799 ￦ 6,788,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,900,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,992,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,459,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

중국의 생물제제 수탁제조 시장 : 개요

중국의 생물제제 수탁제조 시장 규모는 올해 8억 달러에 달했습니다. 이 시장은 예측 기간 중 13%의 CAGR로 확대할 것으로 예측됩니다.

시장 세분화 및 기회 분석은 다음과 같은 매개 변수로 세분화됩니다.

제품 유형

• API
• FDF

사용 발현 시스템

• 포유류 시스템
• 미생물 시스템
• 기타

사업 규모

• 전임상/임상 규모 운영
• 상업 운영

기업 규모

• 소규모 기업
• 중견기업
• 대기업/초대형 기업

생물제제 유형

• 항체
• 백신
• 기타

중국 생물제제 수탁제조 시장 : 성장과 동향

생물제제는 제약 산업에서 가장 빠르게 성장하는 분야 중 하나입니다. 이는 효과적이고 개별화된 약리학적 개입의 필요성으로 인해 이 분야의 기술 혁신이 빠르게 진행되고 있기 때문입니다. 특히 COVID-19 팬데믹의 진원지였던 중국은 세계 2위의 의약품 시장으로 전 세계 원료의약품 생산량의 약 20%를 차지하고 있습니다. 또한 현재까지 25개 이상의 생물제제와 바이오시밀러 제품이 승인되었고, 다양한 생물제제와 바이오시밀러의 연구를 위해 1,000개에 가까운 임상시험이 진행되고 있으며, 중국의 생물제제 수탁제조 시장은 건강한 속도로 성장하고 있습니다. 이와는 별도로, 낮은 제조 비용, 풍부한 상환 정책, 저렴하고 숙련된 노동력의 가용성, 지원적인 규제 상황과 같은 몇 가지 매력은 중국이 생물제제 수탁제조 시장에 종사하는 다양한 이해관계자들에게 매력적인 선택이 될 수 있도록 촉진하고 있습니다.

이 분야에 종사하는 대부분의 위탁 서비스 프로바이더는 틈새 및 신흥 분야에 대한 깊은 경험을 가지고 있다는 점은 주목할 만합니다. 또한 선천적인 전문 지식과 필요한 역량, 인프라의 가용성을 통해 이러한 서비스 제공 업체는 고객의 요구 사항을 효과적으로 충족시킬 수 있으며, 동시에 비용이 많이 드는 간과를 없애고 제품 결함의 가능성을 줄일 수 있습니다.

중국 생물제제 수탁제조 시장 : 주요 인사이트

이 보고서는 중국의 바이오의약품 수탁제조 시장 현황을 조사하고, 잠재적인 성장 기회를 파악하고자 합니다. 주요 조사 결과는 다음과 같습니다.

• 중국의 35개 이상의 CMO/CDMO는 다양한 바이오 치료 제품의 개발 및 제조와 관련된 다양한 서비스를 제공한다고 주장하고 있습니다.
• 여러 기업이 원스톱 솔루션을 제공하며 다양한 규모로 사업을 전개하고 있습니다.
• 현재, 신규 생물제제 생산 능력을 보유하고 있다고 주장하는 기업은 소수에 불과합니다.
• 아시아태평양에서 생물제제의 비즈니스 기회를 확대하기 위해 중국은 CMO에게 선호되는 선택지가 되고 있습니다.

• CMO는 고객과 스폰서의 진화하는 요구에 부응하기 위해 중국내 여러 지역에 시설을 설립하고 있습니다.
• 지난 5년 동안 80건 이상의 거래가 체결되어 이 분야의 제휴 활동이 급증하고 있습니다. 이러한 제휴의 대부분은 항체 기반 제품의 개발 및 제조를 위해 체결된 것입니다.
• 이 분야에서 체결된 파트너십의 수는 지난 수년간 CAGR 21%로 증가했습니다.
• 보고된 거래의 60% 이상이 임상 단계의 분자와 관련하여 체결되었습니다.
• 대형 제약사들도 생물제제를 중심으로 신규 시설 설립, 기존 연구개발센터 확장, 제조시설 보강 등 이 지역에 많은 투자를 하고 있습니다.
• 화이자는 3억 5,000만 달러를 투자하여 중국 항저우에 고품질 바이오시밀러를 생산할 수 있는 최첨단 세계 바이오테크놀러지 센터를 신설하여 국내외 수요에 대응할 예정입니다.
• 머크는 GenScript와 제휴하여 중국 및 세계 시장에서 세포 및 유전자 치료제의 개발 및 상용화를 촉진하기 위해 플라스미드 및 바이러스 벡터 생산 플랫폼을 구축했습니다.

• 이 지역의 CMO 산업은 2030년까지 연평균 13% 성장할 것으로 예측됩니다.

중국 생물제제 수탁제조 시장의 참여 기업 예

• ChemPartner Biologics
• JHL Biotech
• JOINN Biologics
• MabPlex
• Mycenax Biotech
• WuXi AppTec

목차

제1장 서문

제2장 개요

제3장 서론

• 챕터 개요
• 생물제제의 개요
• 생물제제의 제조
• 계약 제조의 개요
• 생물제제 업계에서 아웃소싱의 필요성
• 생물제제 업계에서 일반적으로 아웃소싱되는 업무
• CMO 파트너 선정 기본 가이드라인
• 제조 서비스 아웃소싱의 이점
• 생물제제 계약 제조에 수반하는 리스크와 과제
• 향후 전망

제4장 사례 연구 : 저분자와 대분자의 비교

• 챕터 개요
• 저분자 및 고분자 의약품/치료법

제5장 경쟁 구도

• 챕터 개요
• 중국의 생물제제 수탁제조 업자 : 시장 구도

제6장 기업 개요

• 챕터 개요
• ChemPartner Biologics
• JHL Biotech
• JOINN Biologics
• MabPlex
• Mycenax Biotech
• WuXi AppTec

제7장 파트너십

• 챕터 개요
• 파트너십 모델
• 중국의 생물제제 수탁제조 업자 : 최근 제휴

제8장 최근 확장

• 챕터 개요
• 중국의 생물제제 수탁제조 업자 : 최근 확대

제9장 임상시험 분석

• 챕터 개요
• 범위와 조사 방법
• 임상시험 분석 : 생물제제

제10장 지역 능력 분석

• 챕터 개요
• 전제와 주요 파라미터
• 중국의 생물제제 수탁제조 업자 전체 상황
• 지역적 능력 분석 : 중국 북부 생물제제 수탁제조 업자
• 지역적 능력 분석 : 중국 동부 생물제제 수탁제조 업자
• 지역적 능력 분석 : 중국 중부 생물제제 수탁제조 업자
• 지역적 능력 분석 : 중국 남부 생물제제 수탁제조 업자

제11장 용량 분석

• 챕터 개요
• 전제와 조사 방법
• 중국의 생물제제 수탁제조 업자 : 설치용량
• 결론

제12장 중국에서 대형 제약회사 생물제제 제조구상

• 챕터 개요
• 중국 대형 제약회사 생물제제 연구개발·제조 구상 리스트
• 대형 제약회사의 경쟁 벤치마킹

제13장 제조인가 구입인가 의사 의사결정 프레임워크

• 챕터 개요
• 전제와 주요 파라미터
• 중국의 생물제제 수탁제조 업자 : 제조인가 구입인가 의사결정
• 결론

제14장 시장 규모의 평가와 기회 분석

• 챕터 개요
• 주요 전제와 예측 조사 방법
• 중국에서 생물제제 수탁제조 시장(-2035년)
• 중국의 생물제제 수탁제조 시장(-2035년) : 사용 발현 시스템별
• 중국의 생물제제 수탁제조 시장(-2035년) : 사업 규모별
• 중국의 생물제제 수탁제조 시장(-2035년) : 기업 규모별
• 중국의 생물제제 수탁제조 시장(-2035년) : 생물제제 유형별

제15장 COVID-19별 중국 생물제제 CMO 시장에 대한 영향

• 챕터 개요
• 주요 참여 기업의 현재의 의견과 회복구상
  • WuXi AppTec
  • Boehringer Ingelheim
  • GE Healthcare
  • Lonza
  • AmbioPharm
  • 중국 생물제제 수탁제조 시장에 대한 영향

제16장 SWOT 분석

제17장 중국 생물제제 CMO 시장의 미래

• 챕터 개요
• 아웃소싱 활동은 향후 증가할 것으로 예상된다.
• 단발 계약으로부터 전략적 파트너십으로의 이동
• 혁신적 기술의 도입
• 바이오프로세스에서 설계 품질 원칙의 보급
• 니치 치료 영역에 대한 중점화
• 바이오시밀러 시장이 계약 서비스 매출에 기여
• 원스톱 숍 전문성을 확립하기 위한 능력과 시설의 확장
• 자금 유입과 아웃소싱 예산의 증가
• 스폰서와 서비스 프로바이더가 직면하는 과제
• 결론

제18장 인터뷰 기록

제19장 부록 1 : 표형식 데이터

제20장 부록 2 : 기업·단체 리스트

KSA

영문 목차

영문목차

CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global China biologics contract manufacturing market valued at USD 0.8 billion in the current year is anticipated to grow at a CAGR of 13% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product

• APIs
• FDFs

Expression System Used

• Mammalian Systems
• Microbial Systems
• Other Expression Systems

Scale of Operation

• Preclinical / Clinical Scale Operations
• Commercial Operations

Company Size

• Small Companies
• Mid-sized Companies
• Large / Very Large Companies

Type of Biologic

• Antibodies
• Vaccines
• Other Biologics

CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

Biologics represent one of the fastest growing segments of the pharmaceutical industry. This can

be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized pharmacological interventions. Notably, China which was the epicenter of the COVID-19 pandemic, is the world's second largest pharmaceutical market and accounts for nearly 20% of the global output of APIs. Further, with over 25 biologics and biosimilar products approved till date and close to 1,000 clinical trials being conducted to investigate a variety of biologics and biosimilars, the biologics contract manufacturing market in China is growing at a healthy pace. Apart from this, several benefits, such as lower manufacturing costs, enhanced reimbursement policies, availability of cheap and skilled labor and a supportive regulatory landscape, has facilitated China in becoming an attractive choice for various stakeholders engaged in the biologics contract manufacturing market.

It is worth noting that most of the contract service providers engaged in this domain have profound experience in niche and emerging areas. In addition, the innate expertise and availability of required capabilities, as well as infrastructure, enables such service providers to effectively fulfil the requirements of their clients, while eliminating costly oversights and reducing chances of product failure.

CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the China biologics contract manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products.
• Several players provide one-stop solutions and are capable of operating at various scales; the landscape includes a mix of both established players and new entrants.
• At present, only a handful of firms claim to have capabilities for the manufacturing of novel biologics.
• In order to tap the increasing opportunity for biologics in Asia-Pacific, China has emerged a preferred choice for CMOs.

• To cater to the evolving needs of clients / sponsors, CMOs have established facilities across different regions of China; Eastern China, with the maximum number of sites, has emerged as a manufacturing hub.
• With over 80 deals inked in past five years, there has been a surge in the partnership activity within this domain; majority of these collaborations were signed for the development and manufacturing of antibody-based products.
• The number of partnerships signed within this domain has increased at a CAGR of 21% in the past few years.
• More than 60% of the reported deals were inked in relation to clinical stage molecules.
• Big pharma players have also made significant investments in this region, including establishing new facilities, expanding existing R&D centers and growing manufacturing facilities, focused on biotherapeutics.
• Pfizer invested USD 350 million to establish a new state-of-art global biotechnology center in Hangzhou, China for the production of high quality biosimilars to meet both local and international demand.
• Merck partnered with GenScript to establish a plasmid and viral vector manufacturing platform in order to expediate development and commercialization of cell and gene therapies in Chinese and global market.

• We expect global biopharmaceutical developers to continue to outsource their manufacturing operations to China in the long term; the CMO industry in the region is likely to grow at an annualized rate of ~13%, till 2030.

Example Players in the China Biologics Contract Manufacturing Market

• ChemPartner Biologics
• JHL Biotech
• JOINN Biologics
• MabPlex
• Mycenax Biotech
• WuXi AppTec

CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the China biologics contract manufacturing market, focusing on key market segments, including [A] type of product, [B] expression system used, [C] scale of operation, [D] company size and [E] type of biologic.
• Market Landscape: A comprehensive evaluation of companies offering contract manufacturing services for biopharmaceuticals in China, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] scale of operation, [D] location of headquarters, [E] number of manufacturing facilities, [F] location of facilities, [G] type of business segment, [H] type of manufacturing service(s) offered, [I] type of biologic(s) manufactured, [J] type of expression system(s) used, [K] type of bioreactor(s) used, [L] mode of operation, [M] type of packaging and [N] affiliations to regulatory accreditations and certifications.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the biopharmaceutical manufacturing market in China, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] scale of operation, [D] type of biologic, [E] focus area of the deal, [F] target indication, [G] most active players (in terms of number of partnerships signed) and [H] geography.
• Recent Expansions: A comprehensive evaluation of expansion initiatives undertaken by contract manufacturers in China, based on several relevant parameters, such as [A] year of expansion, [B] type of expansion, [C] scale of operation of manufacturing facility, [D] type of biologic and [E] location of manufacturing facility.
• Clinical Trial Analysis: An insightful analysis of clinical trials related to biopharmaceuticals conducted in China, based on several parameters, such as [A] trial registration year, [B] trial phase, [C] trial recruitment status, [D] type of sponsor / collaborator, [E] geography and [F] number of patients enrolled.
• Capacity Analysis: A detailed analysis of installed capacity for manufacturing biopharmaceuticals in China, based on several parameters, such as [A] company size, [B] scale of operation, [C] key geographical regions and [D] expression system used.
• Big Pharma Initiatives: A comprehensive analysis of the recent initiatives undertaken by big pharma players in China for the manufacturing of biopharmaceuticals, based on various relevant parameters, such as [A] number of initiatives, [B] year of initiative and [C] benchmark analysis of big pharma players.
• Make Versus Buy Decision Making Framework: A detailed qualitative analysis, focusing on the various factors that need to be considered by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
• Company Profiles: In-depth profiles of the companies that have a diverse range of capabilities for the development, manufacturing and packaging of biopharmaceutical products, focusing on [A] overview of the company, [B] financial information (if available), [C] service portfolio, [D] details related to manufacturing capabilities and facilities and [E] recent developments and an informed future outlook.
• Case Study: A detailed comparison of the important characteristics of large and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
• SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of China biologics contract manufacturing market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Overview of Biopharmaceuticals
• 3.3. Manufacturing Biopharmaceuticals
  • 3.3.1. Types of Expression Systems Used
    • 3.3.1.1. Bacterial Expression Systems
    • 3.3.1.2. Yeast Expression Systems
    • 3.3.1.3. Insect Expression Systems
    • 3.3.1.4. Plant Expression Systems
    • 3.3.1.5. Mammalian Expression Systems
    • 3.3.1.6. Fungal Expression Systems
  • 3.3.2. Processing Steps
    • 3.3.2.1. Upstream Processing
    • 3.3.2.2. Downstream Processing
• 3.4. Overview of Contract Manufacturing
  • 3.4.1. Contract Manufacturing Scenario in China
• 3.5. Need for Outsourcing in the Biopharmaceutical Industry
  • 3.5.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
• 3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry
• 3.7. Basic Guidelines for Selecting a CMO Partner
• 3.8. Advantages of Outsourcing Manufacturing Services
  • 3.8.1. Benefits of Engaging Chinese Contract Service Providers
• 3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
  • 3.9.1. Challenges Associated with Engaging Chinese Contract Service Providers
• 3.10. Future Perspective

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES

• 4.1. Chapter Overview
• 4.2. Small Molecule and Large Molecule Drugs / Therapies
  • 4.2.1. Comparison of Key Characteristics
  • 4.2.2. Comparison of Manufacturing Processes
  • 4.2.3. Comparison of Key Manufacturing-Related Challenges

5. COMPETITIVE LANDSCAPE

• 5.1. Chapter Overview
• 5.2. Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape
  • 5.2.1. Analysis by Year of Establishment
  • 5.2.2. Analysis by Company Size
  • 5.2.3. Analysis by Scale of Operation
  • 5.2.4. Analysis by Location of Headquarters
  • 5.2.5. Analysis by Location of Manufacturing Facilities
  • 5.2.6. Analysis by Type of Product
  • 5.2.7. Analysis by Types of Services Offered
  • 5.2.8. Analysis by Type of Biologic
  • 5.2.9. Analysis by Expression System Used
  • 5.2.10. Analysis by Type of Bioreactor Used
  • 5.2.11. Analysis by Mode of Operation of Bioreactor
  • 5.2.12. Analysis by Packaging Form Used
  • 5.2.13. Analysis by Regulatory Accreditations / Certifications

6. COMPANY PROFILES

• 6.1. Chapter Overview
• 6.2. ChemPartner Biologics
  • 6.2.1. Company Overview
  • 6.2.2. Service Portfolio
    • 6.2.2.1. Cell Line Development
    • 6.2.2.2. Process Development
    • 6.2.2.3. Formulation Development
    • 6.2.2.4. Aseptic Filling and Freeze Drying
    • 6.2.2.5. Drug Developability and Manuafcturing Study
    • 6.2.2.6. Container Extractables and Leachables Study
    • 6.2.2.7. Analytical Development and Testing
  • 6.2.3. Manufacturing Facilities and Capabilities
  • 6.2.4. Recent Developments and Future Outlook
• 6.3. JHL Biotech
  • 6.3.1. Company Overview
  • 6.3.2. Service Portfolio
    • 6.3.2.1. Cell Line and Process Development
    • 6.3.2.2. Analytical and Formulation Development
    • 6.3.2.3. cGMP Manufacturing
    • 6.3.2.4. Quality Systems
    • 6.3.2.5. Regulatory Support
    • 6.3.2.6. Project Management Services
  • 6.3.3. Manufacturing Facilities and Capabilities
  • 6.3.4. Recent Developments and Future Outlook
• 6.4. JOINN Biologics
  • 6.4.1. Company Overview
  • 6.4.2. Service Portfolio
    • 6.4.2.1. Development Services
    • 6.4.2.2. Manufacturing Services
    • 6.4.2.3. Fill / Finish Services
    • 6.4.2.4. Quality Assurance and Quality Control
  • 6.4.3. Manufacturing Facilities and Capabilities
  • 6.4.4. Recent Developments and Future Outlook
• 6.5 MabPlex
  • 6.5.1. Company Overview
  • 6.5.2. Service Portfolio
    • 6.5.2.1. Development Services
    • 6.5.2.2. GMP Manufacturing Services
  • 6.5.3. Manufacturing Facilities and Capabilities
  • 6.5.4. Recent Developments and Future Outlook
• 6.6. Mycenax Biotech
  • 6.6.1. Company Overview
  • 6.6.2. Service Portfolio
    • 6.6.2.1. Cell Development Services
    • 6.6.2.2. Process Development Services
    • 6.6.2.3. Analytical and Quality Control
    • 6.6.2.4. GMP Manuafacturing Services
  • 6.6.3. Manufacturing Facilities and Capabilities
  • 6.6.4. Recent Developments and Future Outlook
• 6.7. WuXi AppTec
  • 6.7.1. Company Overview
  • 6.7.2. Financial Information
  • 6.7.3. Service Portfolio
    • 6.7.3.1. Discovery Sciences
    • 6.7.3.2. Development Services
    • 6.7.3.3. Testing Services
    • 6.7.3.4. Clinical Manufacturing Services
    • 6.7.3.5. Commercial Manufacturing Services
    • 6.7.3.6. Fill / Finish Operations
  • 6.7.4. Manufacturing Facilities and Capabilities
  • 6.7.5. Recent Developments and Future Outlook

7. PARTNERSHIPS

• 7.1. Chapter Overview
• 7.2. Partnership Models
• 7.3. Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships
  • 7.3.1. Analysis by Year of Partnership
  • 7.3.2. Analysis by Type of Partnership
  • 7.3.3. Analysis by Scale of Operation
  • 7.3.4. Analysis by Type of Biologic
  • 7.3.5. Analysis by Focus Area
  • 7.3.6. Analysis by Therapeutic Area
  • 7.3.7. Most Active Players: Analysis by Number of Partnerships
  • 7.3.8. Geographical Analysis
    • 7.3.8.1. Geographical Distribution by Number of Partnerships
    • 7.3.8.2. Intercontinental and Intracontinental Agreements

8. RECENT EXPANSIONS

• 8.1. Chapter Overview
• 8.2. Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions
  • 8.2.1. Analysis by Year of Expansion
  • 8.2.2. Analysis by Type of Expansion
  • 8.2.3. Analysis by Scale of Operation
  • 8.2.4. Analysis by Type of Biologic
  • 8.2.5. Analysis by Location of Expansion Project
  • 8.2.6. Analysis by Capacity of Expanded Facility
  • 8.2.7. Most Active Players: Analysis by Number of Expansions
  • 8.2.8. Analysis by Region

9. CLINICAL TRIAL ANALYSIS

• 9.1. Chapter Overview
• 9.2. Scope and Methodology
• 9.3. Clinical Trial Analysis: Biologic Drugs
  • 9.3.1. Analysis by Trial Registration Year
  • 9.3.2. Analysis by Trial Phase
  • 9.3.3. Analysis by Trial Status
  • 9.3.4. Geographical Analysis by Number of Clinical Trials
  • 9.3.5. Geographical Analysis by Enrolled Patient Population
  • 9.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
  • 9.3.7. Analysis of Enrolled Patient Population by Trial Phase
  • 9.3.8. Analysi by Type of Sponsor / Collaborator
  • 9.3.9. Most Active Players: Analysis by Number of Registered Trials
  • 9.3.10. Analysis by Clinical Trial Center

10. REGIONAL CAPABILITY ANALYSIS

• 10.1. Chapter Overview
• 10.2. Assumptions and Key Parameters
• 10.3. Overall Landscape of Chinese Biopharmaceuticals Contract Manufacturers
• 10.4. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern China
• 10.5. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China
• 10.6. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China
• 10.7. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern China

11. CAPACITY ANALYSIS

• 11.1. Chapter Overview
• 11.2. Assumptions and Methodology
• 11.3. Chinese Biopharmaceutical Contract Manufactures: Installed Capacity
  • 11.3.1. Analysis by Company Size
  • 11.3.2. Analysis by Scale of Operation
  • 11.3.3. Analysis by Expression System Used
  • 11.3.4. Analysis by Location of Manufacturing Facility
  • 11.3.5. Analysis by Company Size and Location of Manufacturing Facility
  • 11.3.6. Analysis by Scale of Operation and Location of Manufacturing Facility
• 11.4. Concluding Remarks

12. BIG PHARMA BIOPHARMACEUTICAL MANUFACTURING INITIATIVES IN CHINA

• 12.1. Chapter Overview
• 12.2. List of Biopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Players in China
  • 12.2.1. Analysis by Number of Initiatives
  • 12.2.2. Analysis by Year of Initiative
  • 12.2.3. Analysis by Company and Year of Initiative
  • 12.2.4. Analysis by Type of Initiative
  • 12.2.5. Analysis by Type of Biologic
• 12.3. Competitive Benchmarking of Big Pharmaceutical Players
  • 12.3.1. Harvey Ball Analysis: Big Pharma Investment Summary
  • 12.3.2. Geographical Analysis by Investment Made

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

• 13.1. Chapter Overview
• 13.2. Assumptions and Key Parameters
• 13.3. Chinese Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
  • 13.3.1. Scenario 1
  • 13.3.2. Scenario 2
  • 13.3.3. Scenario 3
  • 13.3.4. Scenario 4
• 13.4. Conclusion

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Key Assumptions and Forecast Methodology
• 14.3. Biopharmaceutical Contract Manufacturing Market in China, Till 2035
  • 14.3.1. Biopharmaceutical Contract Manufacturing Market in China for APIs, Till 2035
  • 14.3.2. Biopharmaceutical Contract Manufacturing Market in China for FDFs, Till 2035
• 14.4. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Distribution by Expression System Used
  • 14.4.1. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Mammalian Systems
  • 14.4.2. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Microbial Systems
  • 14.4.3. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Other Expression Systems
• 14.5. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Distribution by Scale of Operation
  • 14.5.1. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Preclinical / Clinical Scale Operations
  • 14.5.2. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Commercial Operations
• 14.6. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Distribution by Company Size
  • 14.6.1. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Small Companies
  • 14.6.2. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Mid-sized Companies
  • 14.6.3. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Large and Very Large Companies
• 14.7. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Distribution by Type of Biologic
  • 14.7.1. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Antibodies
  • 14.7.2. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Vaccines
  • 14.7.3. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Other Biologics

15 COVID-19 Impact on China Biopharmaceutical CMO Market

• 15.1. Chapter Overview
• 15.2. Current Opinions and Recuperative Initiatives of Key Players
  • 15.2.1. WuXi AppTec
  • 15.2.2. Boehringer Ingelheim
  • 15.2.3. GE Healthcare
  • 15.2.4. Lonza
  • 15.2.5. AmbioPharm
  • 15.2.6. Impact on China Biopharmaceutical Contract Manufacturing Market

16. SWOT ANALYSIS

• 16.1. Chapter Overview
• 16.2. Strengths
• 16.3. Weaknesses
• 16.4. Opportunities
• 16.5. Threats
• 16.6. Comparison of SWOT Factors
• 16.7. Concluding Remarks

17. FUTURE OF THE CHINA BIOPHARMACEUTICAL CMO MARKET

• 17.1. Chapter Overview
• 17.2. Outsourcing Activities Anticipated to Increase in Future
• 17.3. Shift from One-time Contracts to Strategic Partnerships
• 17.4. Adoption of Innovative Technologies
  • 17.4.1. Single Use Bioreactors
  • 17.4.2. Novel Bioprocessing Techniques
  • 17.4.3. Bioprocess Automation
• 17.5. Growing Popularity of the Quality by Design Principle in Bioprocessing
• 17.6. Increasing Focus on Niche Therapeutic Areas
• 17.7. Biosimilars Market to Contribute to Contract Service Revenues
• 17.8. Capability and Facility Expansions to Establish One Stop Shop Expertise
• 17.9. Increase in Financial In-flow and Outsourcing Budgets
• 17.10. Challenges Faced by Sponsors and Service Providers
  • 17.10.1. Concerns Associated with Single Use Systems
  • 17.10.2. Issues Related to Capacity Fluctuations
• 17.11. Concluding Remarks

18. INTERVIEW TRANSCRIPTS

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

관련자료